[Skip to Content]
[Skip to Content Landing]
October 1991

Topical Timolol and Serum Lipoproteins-Reply

Author Affiliations

Los Angeles, Calif

Arch Ophthalmol. 1991;109(10):1342. doi:10.1001/archopht.1991.01080100021006

In Reply.  ——We would like to thank Drs Vogel, Shaw, and Weinreb for their observations regarding the design and conclusions of this study. Ideally, a clinical trial should be randomized and double-masked; under the circumstances, this was not feasible. Although there was no placebo control group, each subject served as his or her own control. To determine our lipid profiles at baseline and during therapy, we used mean lipid profiles calculated from two 12-hour fasting blood samples drawn at least 5 days apart before therapy and two blood samples drawn at least 5 days apart during therapy. By using mean lipid profiles, we minimized variation within volunteers. Our patients exhibited a statistically significant difference. The contention that our results may have resulted from the "passage of time" and "external factors such as diet, exercise, and inadvertent counseling by investigators" assumes that, for some reason, the HDL cholesterol level of the